TBD-Biodiscovery is an innovative Estonian company, founded in 2006 by private capital and contributing to modern healthcare and biotech industry. Our business started with contract services and grew up to custom manufacturing of active pharmaceutical ingredients and building up our own products portfolio. Nowadays TBD-Biodiscovery has wide network of partners worldwide (EU, Switzerland, Israel, US, Russia, South Korea and Japan) and has set up regular production of bioluminescence agents and active pharmaceutical ingredients for both human healthcare and veterinary medicines.
Please see our presentation to find out more.
2006 TBD-Biodiscovery is established by entrepreneurs and scientists.
2008 GMP compliance certificate is issued by State Agency of Medicines.
2013 TBD-Biodiscovery has customers worldwide. Semisynthetic technology of Amrubicin is patented in EU. The company contributed to several EU-projects, including MABTOX (development of Antibody Drug Conjugates for cancer therapy).
2015 A daughter company, ToxInvent, is established to pursue the development of proprietary products and technologies (ADC payloads and bioluminescence agents)
2016 TBD-Biodiscovery became global leader on the market of bioluminescence chemicals, including Ultrahigh grade D-Luciferin and D-Luciferin K-salt.
2018 The management system of the company has been certified according to the standard ISO 9001:2015. TBD-Biodiscovery has obtained new office rooms and new warehouses, followed by expansion of API manufacturing capabilities: two additional rooms are qualified for GMP-regulated production.